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Heart failure in congenital heart disease: prevalence and outcome 
Improved medical care of congenital heart disease patients increased survival into adulthood from 
15% in the 1960s to over 85% in the current era. As a consequence, the prevalence of adult congenital 
heart disease (ACHD) increased rapidly,
1
 which is estimated to be >1 million ACHD patients in North 
America and 1.2 million in Europe. The growing number and aging of ACHD patients led to an overall 
increase in hospitalizations over the last decade and a substantial increase in patients presenting with heart 
failure (HF) (∼20%).2 
 
The incidence of first HF-admission was 1.2 per 1000 patient-years in the Dutch national ‘CONCOR’ 
registry. Patients admitted with HF had a five-fold higher risk of death than those not admitted. From the 
same registry, the mortality was 2.8% during a follow-up period of 24 865 patient-years. Chronic HF 
(26%) and sudden death (19%) were recorded most frequently. The median age at death from HF was 
51.0 years (range: 20.3–91.2 years).
3
 In another ACHD cohort, sudden death (26%) was the most 
common cause of death, followed by progressive HF (21%) and perioperative death (18%).
4
 Although 
patients with ACHD may not readily report symptoms, clinical HF is documented in 22.2% of patients 
with a Mustard repair for transposition of the great arteries (TGAs), 32.3% with congenitally corrected 
transposition of the great arteries (ccTGA), and 40% of patients after Fontan palliation. 
  
Pathophysiology of heart failure in adult congenital heart disease 
Heart failure with impaired systolic ventricular function 
The aetiology and triggers of impaired systolic ventricular function in ACHD patients are summarized 
in Table 1.  
Table 1. Pathophysiology of heart failure with impaired systolic function: triggers (examples) 
 
1. Systolic dysfunction of the systemic morphological left ventricle  
– Pressure overload (sub-, supravalvular or valvular aortic stenosis, coarctation of the aorta)  
– Volume overload (aortic valve regurgitation, VSD, patent ductus arteriosus, or mitral regurgitation)  
– Myocardial injury (limited myocardial protection during bypass, ventriculotomy)  
– Altered myocardial architecture (non-compaction)  
– Altered geometry of the sub-pulmonary ventricle interfering with diastolic filling of the systemic ventricle (severe 
pulmonary regurgitation in ToF)  
2. Systolic dysfunction of the sub-pulmonary morphological right ventricle  
– Volume overload (severe pulmonary regurgitation in ToF, atrial septal defect with large left-to-right shunt)  
– Pressure overload (severe RV outflow tract obstruction)  
3. Systolic dysfunction of the morphological systemic right ventricle  
– Pressure overload [congenitally corrected transposition of the great arteries, dextro-transposition of the great arteries after 
atrial switch repair (Mustard or Senning)]  
– Myocardial injury by functional ischaemia (single right coronary artery)  
4. Systolic dysfunction of the systemic single ventricle  
– Volume under-load after initial volume overload (Fontan repair)  
– Myocardial injury (limited myocardial protection during bypass, ventriculotomy)  
– Myocardial architecture  
5. Systolic dysfunction of the cyanotic systemic and/or sub-pulmonary ventricle with or without pulmonary hypertension  
– Myocardial injury by chronic hypoxia (VSD with pulmonary stenosis)  
– Pressure overload (Eisenmenger syndrome)  
6. Acquired ischaemic heart disease and ventricular dysfunction  
– Cardiovascular risk factors (hypertension, hyperlipidaemia, diabetes mellitus, smoking)  
– Congenital coronary artery abnormalities (anomalous origin and/or course, extrinsic compression by a dilated pulmonary 
artery, coronary kinking after re-implantation of coronary arteries)  
7. Systolic dysfunction of the systemic ventricle due to tachyarrhythmias  
 
 
Heart failure with preserved systolic ventricular function 
This occurs less often in ACHD patients, but is associated with specific conditions such as Shone 
complex and restrictive right ventricular (RV) physiology in the context of pulmonary atresia, ventricular 
septal defect (VSD), and major aorto-pulmonary collateral arteries. 
  
Genetic and neurohormonal background 
Heart failure in ACHD is the result not only of a structural defect but also of defective contractility or 
conduction. An intriguing and emerging hypothesis is that genes involved in morphogenesis during early 
development also play a key role in regulating myocardial function and the responses to physiological 
stress in both the developing and the adult heart.
9
 Adult congenital heart disease patients, rather than 
developing HF as a result of myocyte loss (myocardial infarction) or of intrinsic abnormalities in 
myocardial components (inherited cardiomyopathies), may, according to this predisposing genetic model, 
develop easier HF due to persistent abnormal cardiac pressure, volume, tension, and flow. Furthermore, it 
has been shown that all types of congenital heart disease cause neurohormonal activation of the 
natriuretic, endothelin, sympatho-adrenergic, and renin–aldosterone systems.
5
 
Comorbidities and heart failure in adult congenital heart disease 
Liver disease occurs in patients with ACHD. Elevated systemic venous pressures might lead to liver 
stiffness
6
 and cardiac liver cirrhosis.
7
 Liver disease is mostly associated with a failing Fontan circuit.
8
 
Combined heart liver transplantation is in the end needed when a failing ventricle presents with liver 
cirrhosis.
9
 Also protein loosing enteropathy (PLE) occurs in a failing Fontan. Elevated systemic venous 






 between the systemic 
venous return and the pulmonary venous atrium, allowing right-to-left shunt, might reduce PLE. Also oral 
steroids
12
 as budesonide might improve symptoms and stabilize serum albumin levels; however, its long-
term effect remains unclear. Plastic bronchitis is a rare complication after Fontan palliation.
13
 Elevated 
central venous pressure and low cardiac output likely contribute to the formation of tracheobronchial 
casts. Haemodynamic optimization and aggressive pulmonary vasodilation might improve the clinical 
course. Approximately 30–50% of ACHD patients have significantly impaired renal function.
14
 The risk 
of chronic kidney disease is higher in cyanotic disease, but also present in non-cyanotic diseases. As such, 
stringent blood pressure control and reduction of proteinuria are obligatory. Finally, some haematological 
disorders might occur, mainly in ACHD patients with chronic systemic cyanosis. Haematocrit levels are 
increased,
15
 which leads to high blood viscosity and a low flow phenomenon. The latter might trigger 
thrombosis. In contrast, bone marrow dysfunction leads to a lower number and dysfunctional platelets and 




Diagnostic approach in heart failure 
Knowing the baseline heart defect and the history of surgeries and/or percutaneous interventions is 
mandatory in HF ACHD patients. Diagnosing HF may be difficult as patients often fail to recognize in 
themselves subtle changes in functional class. Patients might have no typical HF symptoms and signs, 
despite reduced exercise capacity and reporting New York Heart Association (NYHA) functional class 
I.
17
 Heart failure is therefore a clinical syndrome with a diagnosis based on history, examination, and 
investigations. Determining the cause of HF is important, as it may be reversible due to a new or 
worsening residual haemodynamic lesion or an another medical problem, e.g. thyroid dysfunction 





Figure 1. Diagnosis–treatment algorithm. CPET, cardiopulmonary exercise test; PVO2, peak oxygen consumption; LV, left 
ventricle; RV, right ventricle. *Two-fold increase of baseline natriuretic peptide value within 6 months. **>25% decrease of peak 
oxygen consumption. 
Clinical symptoms and signs 
Heart failure symptoms and signs are described in the European Society of Cardiology (ESC) 
guidelines (Table 2 adapted from ESC HF guidelines).
18
 Some patients with complex congenital heart 
disease may have worsening cyanosis in the context of intra- or extra-cardiac shunts or fenestrations. Of 
note, arrhythmias are closely related to HF symptoms and may be the first clinical manifestation of HF.  
  
Table 2. Signs and symptoms of heart failure in congenital heart disease 
Symptoms of systemic ventricular failure  Signs of systemic ventricular failure  
  
Fatigue  Third or fourth heart sound (gallop)  
Breathlessness  Laterally displaced apical impulse  
Dry cough especially lying flat  Pulmonary crepitations  
Reduced exercise tolerance  Absent BS and dull percussion lung bases due to pleural effusions  
Orthopnoea    
Paroxysmal nocturnal dyspnea    
Wheezing    
Symptoms of sub-pulmonary ventricular failure  Signs of sub-pulmonary ventricular failure  
Fatigue  Elevated JVP  
Bloating  Hepatomegaly  
Weight gain (> 2kg/week)  Ascites  
Loss of appetite  Pitting leg oedema, sacral oedema, scrotal oedema  
Reduced exercise tolerance    
Increased abdominal girth    
Symptoms of congestive (biventricular) failure  Signs of congestive (biventricular) failure  
Combined systemic and sub-pulmonary symptoms  Combined systemic and sub-pulmonary signs  
  
 
BS, breath sounds; JVP, jugular venous pressure. 
Electrocardiography 
Many ACHD patients have baseline abnormal electrocardiograms (ECGs) with prolonged QRS 
duration, other intra-ventricular conduction delay, nodal rhythm, and LV (left ventricular) or RV 
hypertrophy. A change in ECG morphology is therefore most relevant in the ACHD patient. However, 
each ECG has to be looked after atrio-ventricular (AV) conduction abnormalities (i.e. complete AV block 
in ccTGA) or for ‘inappropriate’ apparently sinus tachycardia that may mimic atypical supraventricular 
re-entrant tachycardia. 
Imaging 
A chest X-ray easily identifies pulmonary congestion and effusions. The position and size of the heart, 
size of pulmonary arteries and thoracic aorta, and concomitant lung and thorax pathology are simply 
obtained. 
 
Echocardiography allows to: Recommendations have been recently published for tetralogy of Fallot 
(ToF) imaging.
19
Three-dimensional (3D) echocardiography is more sensitive than 2D for the assessment 
of ventricular function and volumes and valves. Transoesophageal echocardiography may also be 
indicated.
20
Stress echocardiography helps assessing contractile reserve
21,22
 and diagnoses acquired heart 
disease such as coronary artery disease (CAD). 
  
 Establish or confirm the underlying congenital heart disease diagnosis 
 Identify concomitant/residual lesions and sequelae 
 Assess ventricular function (sub-aortic–sub-pulmonary) 
 Monitor disease progression 
 Detect new ± acquired lesions 
 Guide further interventions 
 
Magnetic resonance imaging (MRI) is the golden standard for volumetric measurements, ventricular 
function, assessment of vessels, and detection of myocardial fibrosis. European Society of Cardiology 




Computed tomography is particularly good for imaging stented valves and coarctation stents along 




Cardiac catheterization provides detailed haemodynamic data for calculating pulmonary vascular 
resistance and for proceeding to structural interventions.
24
 Other indications include assessment of LV 
and RV diastolic function, pressure gradients, and shunt quantification. Coronary angiography and the 
evaluation of extra-cardiac vessels such as aorto-pulmonary collateral arteries may be indicated.
25
 
Cardiopulmonary exercise and lung function test 
Cardiopulmonary exercise test is a valuable tool with prognostic implications.
26
 The exercise capacity 
is reduced in ACHD patients.
17
 The expected peak oxygen consumption varies between different types of 
ACHD lesions, and reference values for exercise limitations have been published.
27
 There is a good 
correlation between exercise test results and mortality that seems to be increased in patients with peak 
oxygen consumption (VO2) values <15 mL/min/kg. Other prognostic parameters such as ventilator 
response
28
 and oscillatory patterns
29
 provide important clinical information. Lung function test is needed 
to detect concomitant broncho-pulmonary disease. 
Laboratory testing 
Adult congenital heart disease patients suspected for HF should undergo basic laboratory testing 
including full blood count, renal function, liver function, protein and albumin, iron, and thyroid function. 
Laboratory testing may reveal treatable conditions. Anaemia, renal and liver dysfunction, 




B-type natriuretic peptide (BNP) and N-terminal pro–BNP (NT-proBNP) are related to disease 
severity and prognosis in HF patients with acquired heart disease.
30
 Natriuretic peptides might be also 
clinically important in congenital heart disease.
5,31,32
 A recent cross-sectional study showed that BNP 
correlated with age was higher in women than in men, and differed per diagnosis.
33
 Disease-specific 




B-type natriuretic peptide levels are mildly increased in patients with unrepaired and repaired atrial 
septal defect or VSD.
34
 Shunt severity and pulmonary artery pressures correlate strongly with BNP 
levels.
36,37
 A clear association between BNP and functional class is demonstrated. 
  
Tetralogy of Fallot 
Studies in ToF patients showed correlations between plasma BNP, RV dilation, and severity of 
pulmonary valve regurgitation.
38,39
 Also correlations between BNP and exercise capacity were found.
39,40
 
Most studies to date present only cross-sectional data.
41–50
 B-type natriuretic peptide levels before 
pulmonary valve replacement were found elevated and decrease afterwards; however, the results of 




Systemic morphological right ventricle 
A clear correlation was found between BNP and systemic RV function.
35
 One study showed a 
correlation between RV ejection fraction and atrial natriuretic peptide (ANP).
51
 Extensive atrial scarring 
in Mustard and Senning patients may contribute to elevated ANP levels. Moreover, a strong correlation 
was observed between plasma BNP and the severity of tricuspid regurgitation (TR).
52–59
 One longitudinal 
study described adult patients after atrial switch surgery for TGA.
60
 They found that BNP was the most 
prominent predictor for HF, transplantation, and death (hazard ratio of 21). B-type natriuretic peptide 
might therefore be useful for risk assessment. 
Hypoxia and single ventricle 
Most studies found no correlation between oxygen saturation and BNP.
61–64
 B-type natriuretic peptide 
levels in asymptomatic Fontan patients were comparable with those of healthy controls. However, in 
symptomatic patients, there was a strong correlation between BNP and the severity of HF. One study 
found significantly higher levels of BNP in five patients who died from HF,
62
 while another found no 
prognostic value of BNP.
65
 B-type natriuretic peptide measurement may be useful in symptomatic 
patients. 
Medical treatment 
Systolic failure of the morphological systemic left ventricle 
Trials with hard clinical endpoints have not been done in ACHD patients. The current ESC guidelines 
for HF
18
 suggest that diuretics, renin–angiotensin–aldosterone system (RAAS) blockers, β-blockers, and 
mineralocorticoid receptor antagonists can be used in the congenital heart disease population, mainly 




There is theoretical evidence to support the use of angiotensin-converting enzyme inhibitors (ACEIs) 
and, if not tolerated, angiotensin receptor blockers (ARB) in the treatment of asymptomatic or 
symptomatic HF ACHD patients. Similarly, the evidence for using β-blockers, such as carvedilol, 
metoprolol, bisoprolol, and nebivolol, may also be extrapolated to the ACHD population. Preliminary 
data suggest a favourable effect of these drugs in HF secondary to aortic
69,70




Many of these medications are prescribed for other indications, such as high blood pressure or 
arrhythmias, and this allows initiating drug treatment despite missing evidence in ACHD. Any treatment 
should serve one of two purposes: to improve prognosis or to alleviate symptoms. Loop diuretics never 
showed improved survival in chronic HF patients
18
 but relief symptoms such as dyspnoea and peripheral 
oedema. Digoxin, once widely used in HF, now has a more limited role, as there is no mortality benefit 
when compared with placebo. 
  
Systolic failure of the morphological systemic right ventricle 
A systemic RV will gradually fail.
72–74
 Extrapolating the ESC HF guidelines
18
 to this ACHD group is 
more difficult. The cut-off of impaired ejection fraction of a systemic LV at which drug treatment has 
clinical benefit is well defined. However, no such data exist for the systemic RV. In most adults with a 





For an asymptomatic patient without signs of HF, it is difficult to know if and when to initiate HF 
treatment. Patients with stable systemic RV function have not always an activated neurohormonal and 
cardiac autonomic nervous system. Therefore, blocking the RAAS does not result in better clinical 
outcome,
77–79
 although surrogate endpoints (exercise duration, degree of systemic AV valve regurgitation) 
seem to be influenced positively,
78,80
 Caution is required when using drugs that venodilate and reduce 
preload in Mustard or Senning patients. Ventricular filling is significantly compromised by concomitant 
baffle obstruction. β-Blockers might improve functional capacity and surrogate endpoints such as the 
severity of systemic AV valve regurgitation and RV remodelling.
81–83
 However, patients with Mustard or 
Senning repair or with ccTGA are all susceptible to conduction abnormalities. 
 
In symptomatic patients with neurohormonal and cardiac autonomous nervous system activation, 
standard HF treatment might offer theoretical benefit
84,85
 and is therefore suggested to be administered as 
in patients with a failing LV. 
Systolic failure of the morphological sub-pulmonary right ventricle 
No randomized controlled trials investigated which drugs to use. The beneficial effects of RAAS 
blockade or β-blockers have never been studied. Lack of data on the failing sub-pulmonary RV implies 
only few recommendations in the ESC guidelines on HF
18
 or pulmonary hypertension.
86
 No medical 
treatment is indicated in asymptomatic patients. Diuretics are mainly the treatment of a symptomatic 
patient. Thiazides can be added in more resistant cases of oedema and act synergistically with loop 
diuretics, but then renal function and biochemical markers need close surveillance.
87
 If RV failure is 
secondary to pulmonary arterial hypertension, drug therapy mainly focuses on the pulmonary circulation 
using endothelin receptor antagonists, phosphodiesterase inhibitors, or prostacyclines. 
Systolic failure of the single ventricle 
Phosphodiesterase inhibitors or endothelin receptor antagonists may improve ventricular function in a 
Fontan patient, when increasing pulmonary vascular resistance impairs ventricular filling. In patients 
treated with sildenafil, pulmonary vascular resistance decreases,
82





 The effect of bosentan in the Fontan patient is less certain. Some 
studies suggest a beneficial effect,
90
 whereas others did not.
91
 Perhaps, the combined increase in preload 
and reduction in afterload, which is more pronounced with sildenafil treatment, improves more the 




Primary myocardial dysfunction in Fontan requires standard HF medication for symptom relief in 
both, morphological left and right ventricles. However, in an asymptomatic patient with an impaired 
systemic right ventricle, the effect of medical treatment is unclear. Loop diuretics are frequently used if 
there is pulmonary fluid overload, but too high a dose can reduce preload and lead to the cardio-renal 
syndrome. Spironolactone appears to have an impact on PLE
11
 and endothelial function.
93
 One study 
showed that enalapril did not enhance exercise capacity in Fontan patients.
94
 The indication for RAAS 
blockers in the Fontan is uncertain. Carvedilol has been shown to improve HF signs and symptoms.
95,96
 In 
summary, reducing pulmonary vascular resistance and afterload seems to have most clinical benefit, 
while symptomatic treatment with diuretics should be used cautiously and judiciously. 
  
Standard HF treatment of patients with a functional univentricular heart and intra-cardiac shunt 
implies a difficult balance. Peripheral or pulmonary oedema can be treated with loop diuretics. However, 




Heart failure with preserved ejection fraction 
No treatment reduced morbidity and mortality in patients with preserved ejection fraction (ESC 
guidelines on HF
18
). Diuretics are used for symptom relief, and β-blockers may help by prolonging 
ventricular filling. 
 
No studies in ACHD looked at ivabradine. However, in case of therapy resistance, ivabradine can be 
prescribed with similar indications as listed in the HF ESC guidelines.
18
 The same is true for hydralazine 
and isosorbide dinitrate. However, both agents decrease substantially the systemic vascular resistance so 
that systemic oxygen saturation has to be followed meticulously (see lower). Recommendations are 
summarized in Table 3.  
  
Table 3. Medical treatment for heart failure related to intrinsic myocardial dysfunction 
   
Systolic HF      
Systemic ventricle      
 Morphological left ventricle (EF < 40%)  Asymptomatic or symptomatic  RAAS blockers 
β-Blockers 
Mineralocorticoid receptor antagonists 
Diuretics (loop and thiazide) 
Digoxin  
 Morphological right ventricle (EF < 40%)  Asymptomatic  No medical treatment  
Symptomatic  RAAS blockers 
Beta-blockers 
Mineralocorticoid receptor antagonists 
Diuretics (loop and thiazide) 
Digoxin  
Sub-pulmonary ventricle  
 Morphological left or right ventricle (EF < 40%)  Asymptomatic  No medical treatment  
  Symptomatic  Diuretics (loop and thiazide) 
Mineralocorticoid receptor antagonists 
Pulmonary vasodilators (PAH) 
Single ventricle      
 Fontan circulation (EF < 40%) 
Morphological left ventricle  
Asymptomatic  RAAS blockers 
β-Blockers 
Mineralocorticoid receptor antagonists 
Digoxin  
 Morphological right ventricle  Asymptomatic  No medical treatment  
 Morphological left and right ventricle  Symptomatic  RAAS blockers 
β-Blockers 
Mineralocorticoid receptor antagonists 
Diuretics (loop and thiazide) 
Digoxin  
 Persistent right-to-left shunt  Asymptomatic  No medical treatment  
Symptomatic  Diuretics (loop and thiazide) 
Agents reducing afterload  
HF with preserved EF  
  Asymptomatic  No medical treatment  
  Symptomatic  Diuretics (loop and thiazide) 
β-Blockers 
Rate-limiting calcium channel blocker 
   
 
EF, ejection fraction; PAH, pulmonary arterial hypertension; PAP, pulmonary arterial pressure. 
 
Iron deficiency has been reported in stable HF patients and in patients hospitalized for worsening 
HF.
98,99
 In the non-congenital population, iron replacement improves functional capacity, symptoms, and 
quality of life (QoL) and reduces the number of HF hospitalizations.
100
 Although no specific trials on iron 
replacement exist in HF ACHD patients, a similar beneficial effect might be expected. Indeed, iron 
deficiency is not uncommon in ACHD patients,
101,102
 and replacement might improve functional 
capacity.
103
 In contrast, vitamin B12 and folate deficiency are relatively rare in patients with chronic 
HF,
104
 and the effect of replacement on outcome, including HF ACHD patients, needs further 
investigation. Some data suggest that the use of anti-platelet therapy or oral anticoagulants may improve 
outcome in advanced HF.
105
 This has never been investigated in HF ACHD patients, but it might be 
considered beneficial in HF secondary to ischaemic heart disease or atrial arrhythmia. 
  
Acute heart failure in adult congenital heart disease patients 
There are no scientific trials to guide clinicians on specifically managing ACHD patients with acute 
HF. Nevertheless, most of the ESC guidelines for managing acute HF
18
 can be applied in this context, 
taking into account the greater complexity and varied co-morbidities on a case-by-case basis. For 
example, in patients with pulmonary hypertension and/or persistent intra- or extra-cardiac shunts, the 
balance between pulmonary vascular resistance and systemic vascular resistance must be borne in mind 
and is a crucial consideration when prescribing pharmacotherapy.
106
 Any increase in pulmonary vascular 
resistance will decrease cardiac output, and, in the presence of an intra-cardiac shunt, any decrease in 
systemic vascular resistance will increase the likelihood of right-to-left shunting and systemic 
desaturation. Triggers that increase pulmonary vascular resistance (hypoxia, hypercapnia, high 
haematocrit, positive pressure ventilation, cold, metabolic acidosis, and alpha-adrenergic stimulation) and 
those that decrease systemic vascular resistance (vasodilators, general anaesthesia, and hyperthermia) 
must therefore be avoided where possible.
106
 Moreover, if there is a persistent right-to-left shunt, there is 
a risk of paradoxical air or thromboemboli and intravenous lines must be meticulously managed 
preferably with bubble filters attached. Patients with cyanosis have a secondary erythrocytosis and both 
an increased bleeding and thrombosis risk, which is generally more pronounced in the setting of acute 
HF. Coagulation factors and platelets should therefore be monitored, iron deficiency corrected, and 
venesection considered if the haematocrit exceeds 65%. 
 
Cardiac monitoring of the ACHD patient in acute HF must also take into account the underlying 
congenital lesion, e.g. the patient with a subclavian flap repair of coarctation of the aorta should have 
blood pressure measured in the right arm as the left subclavian has been used for the repair, or placement 
of a central line in a Fontan patient, which sits in the pulmonary artery, and is therefore not a reliable 
measure of systemic venous filling pressure.
106 
 
Finally, if maximal medical treatment fails to stabilize the haemodynamics, then extra-corporal 
membrane oxygenation (ECMO) and or ventricular assist device (VAD) therapy should be considered as 
bridging therapy to transplantation. 
Cardiopulmonary and physical rehabilitation in adult congenital heart disease patients with heart 
failure 
Cardiopulmonary rehabilitation is since long time recommended in patients with chronic HF.
18,107
 
Indeed, exercise training is safe and tends to benefit clinical outcome.
108,109
 In HF ACHD patients, no 
specific studies have been conducted to evaluate clinical outcome. However, exercise training seems to 
improve safely exercise-related and haemodynamic variables in complex congenital heart disease.
110–112
 
Moreover, cardiac rehabilitation programmes improve QoL in ACHD; however, none of them suffered 
from HF.
113
 Cardiac rehabilitation is probably safe and beneficial. However, further research is needed. A 
recent position paper recommends individualized exercise prescription to improve long-term health 
behaviour, and includes also advice for HF ACHD patients.
114
 
Device therapy in adult congenital heart disease patients with heart failure 
Indications for implantable cardioverter defibrillator therapy 
The incidence of sudden cardiac death (SCD) in the congenital heart disease population is low (<0.1% 
per year) and 5–10 times lower than in the Multicenter Automatic Defibrillator Implantation Trial 
(MADIT) II population.
115
 However, SCD accounts for 20–25% of late deaths in ACHD patients.
4,116
 
There are subgroups of congenital heart disease patients carrying a slightly higher SCD risk such as 
patients after surgical repair of ToF, d-TGA with Mustard or Senning repairs, ccTGA, Eisenmenger 
syndrome, and Ebstein anomaly of the tricuspid valve.
116
 In ACHD patients, consensus exists on 
implantable cardioverter defibrillator (ICD) therapy for secondary prevention of SCD.
115
 Implantable 
cardioverter defibrillator therapy is recommended in survivors of SCD due to ventricular fibrillation (VF) 
or unstable ventricular tachycardia (VT) without reversible cause, patients with documented spontaneous 
sustained VT (sVT) that is not amenable to ablation or surgery, and syncope of unknown origin with 
inducible sVT/ VF at electrophysiology (EP) study or a high suspicion of ventricular arrhythmias being 
the cause of syncope. 
 
Selection of ICD candidates for primary prevention of SCD still remains challenging. In general, 
prophylactic ICD therapy is also indicated in those patients who meet the same standard criteria as 
patients with ischaemic or non-ischaemic cardiomyopathy, i.e. the presence of biventricular physiology 
with a systemic LV ejection fraction <35% and NYHA class II or III symptoms.
117–122 
 
Non-sVT (nsVT) in ToF patients is significantly associated with inducible sVT by programmed 
ventricular stimulation and that inducible sVT carries a five-fold higher rate of clinical VT or SCD.
123
 
Moreover, a weighted risk score to predict appropriate ICD shocks in ToF patients with prophylactic ICD 
implantation has been developed, implementing additive factors of risk stratification such as left ventricle 
end-diastolic pressures, nsVT, inducible sVT, prior shunt, prior ventriculotomy, and QRS duration.
124
 
According to this risk score, prophylactic ICD therapy should be recommended in selected adults after 
ToF repair classified in the high-risk category. However, the management of inappropriate shocks due to 




In contrast, the predictive value of EP testing in other ACHD subgroups is limited or not known. In 
patients with an atrial switch repair, inducible sVT/VF does not predict clinical events.
126
 However, in 
this subgroup of patients, a reduced ejection fraction of the systemic right ventricle has been associated 
with a higher incidence of ventricular tachyarrhythmias and SCD.
127
 For patients with univentricular 
hearts and a Fontan palliation, no recommendations for ICD indications exist. Nevertheless, ICD therapy 
may be reasonable in adults with an impaired single or systemic RV ejection fraction and the presence of 
additional risk factors such as complex ventricular arrhythmias, unexplained syncope, NYHA functional 
class II and III symptoms, long QRS duration, or severe AV valve regurgitation. Implantable cardioverter 
defibrillator therapy is not recommended in ACHD patients and in patients with advanced pulmonary 
vascular disease (Eisenmenger syndrome),
128,129
 drug-refractory NYHA class IV who are not candidates 




Indications for cardiac resynchronisation therapy 
Cardiac resynchronization therapy (CRT) is an established treatment option in LV electromechanical 
dyssynchrony. If response to CRT is positive, reverse remodelling of the LV, functional improvement, 
and a reduction in HF associated morbidity and mortality can be seen.
130,131
 In ACHD patients, the 
morphological heterogeneity of the underlying heart defects makes it far more difficult to define the role 
of CRT. Most of the studies available are retrospective in nature and follow-up time in all trials is limited 
to a few months (4.8–8.4 months); hence, the impact of CRT on long-term morbidity and mortality is not 
known. Surrogate parameters such as metrics of systemic ventricular function or functional parameters 
such as NYHA class were used to define CRT response. Despite these limitations, the following 
observations were made: (i) the majority of congenital heart disease patients included (58%) were in 
NYHA class II when compared with NYHA class III or IV patients with ischaemic or idiopathic dilated 
cardiomyopathy; (ii) the presence of a systemic LV predicted a better CRT response than a systemic 
RV
132
; (iii) the best CRT response was seen in patients with a systemic LV which were converted to CRT 
from conventional RV pacing
133,134
; (iv) the proportion of non-responders to CRT was ∼10–14% in 
congenital heart disease patients and lower than in patients with ischaemic or idiopathic dilated 
cardiomyopathy; and (v) patients with single ventricle morphology may benefit from CRT using 
optimized pacing sites.
132,135
 In general, CRT can be recommended in ACHD patients and patients with 
NYHA class II–IV symptoms, an impaired systemic ventricular ejection fraction, systemic ventricular 
dilation, and prolonged QRS duration. Moreover, upgrading to CRT should be considered in congenital 
heart disease patients with systemic LV and permanent RV pacing resulting in LV dyssynchrony and 
dysfunction. Cardiac resynchronisation therapy should also be considered in NYHA class IV patients as a 
bridge/delay to mechanical assist device therapy or HT. Remote monitoring of devices has been shown to 
reduce adverse outcomes in ICD patients with acquired heart disease,
136
 but may also be beneficial in 
ACHD patients for the early detection and treatment of tachyarrhythmias.
137
 
Heart transplantation and assist devices 
According to the 2014 International Society for Heart Transplantation (ISHLT) Registry, ACHD 
represents ∼10% of the HT indications in patients of 18–30 years.138 Although short-term outcomes are 
worse in ACHD than to those with non-ACHD (20–30% at 30 days mortality in ACHD patients), late-
term survival of ACHD is improved and survival at 10 years is similar between patients with ACHD and 




The outcomes after ACHD HT can vary according to different diagnosis and may be influenced by 
centre's expertise.
138
 Timing of assessment for HT remains challenging, as accurate prediction of 
prognosis is difficult. There is no single prognostic variable to be able to provide a perfect discriminatory 
capacity on need for or timing of HT. Serial cardiopulmonary exercise testing and other prognostic 
variables such as hospitalizations, clinically relevant arrhythmia, symptomatic HF, PLE, and plastic 
bronchitis may help to differentiate those ACHD patients from who do not deserve to be assessed for HT. 
 
Careful pre-transplant evaluation should be specifically done to assess pulmonary vascular resistance; 
the presence of disease in organ systems that could affect post-HT care and can (or cannot) be reversed 
with HT; the presence of chronic or previous infections that could affect both pre- and post-HT 
management; psychosocial evaluation of the patient and caregivers; patency of major veins and arteries; 
human leucocyte antigen sensitization; and surgical risk (multiple cardiac redo operations, great vessels 
anatomy). 
 
Ventricular assist devices (VADs) may be used as destination therapy or bridging to HT in ACHD 
patients.
141
 However, such patients listed for HT have less likelihood to have a VAD as a bridge to HT, 
longer waiting time in status 2, and higher mortality risk in the waiting list.
142
 Several case reports 
describe successful use of LV assist devices in failing systemic right ventricles.
143,144
 However, 
complication rates remain relatively high and are related to anatomic complexity and associated 
morbidities (coagulopathy, liver cirrhosis, etc.). Ventricular assist devices might be applicable in a failing 
Fontan circulation, however, only in these patients with systolic ventricular failure.
145,146
 In case that the 
sub-pulmonary ventricle (as after Fallot repair) fails, an RV assist device might be useful, but clinical 
outcome data are lacking.
141
 
Management of care, psychological issues, and nursing management 
The complexity of most heart diseases leads to a systematic follow-up in specialized ACHD centres. 
Less complex and stable patients are frequently followed in secondary care centres. They have to be 
aware of the occurrence of HF and to detect it in its early stage. Especially in complex cases or cases in 
which evidence-based medicine is lacking, transfer to a specialized ACHD centre is preferred. This might 
be important when HF becomes drug therapy resistant, and bridging to or listing for HT is needed. 
 
Frequency of follow-up is reported in the ESC guidelines for the management of grown-up congenital 
heart disease.
25
 Annual check-up of an HF ACHD patient, even asymptomatic, is recommended. This is 
important for optimizing health behaviour and treatment adherence. Follow-up visits and educational 
interventions contribute to persons' well-being and improve the level of patients' knowledge on the 
condition of their heart. Depending on the (proceeding) symptomatology and (in)stability of the disease 
process, more frequent follow-ups become obligatory. Routine follow-up implies focus on risk factors (as 
palpitations, syncope), clinical examination, and electrocardiographic and echocardiographic evaluation. 
Depending on the symptomatology, changes in BNP levels need to be controlled, 24 h Holter/bicycle 
testing is indicated, and if the patient remains unstable, invasive evaluation will be preferred. 
 
Sexual activity is not harmful for the heart, advice for pregnancy, contraception and labour in the 
female subgroup, and recommendations about physical activities are discussed in the ESC guidelines on 
pregnancy
147
 and the ESC position paper about physical activities in ACHD.
148 
 
Many patients with congenital heart disease deal with social and psychological concerns that may 
influence QoL.
149
 Psychosocial condition refers to a range of issues faced by adults with congenital heart 
disease including the ‘feeling of being different’, experiences related to the living with the congenital 
heart disease and possible exacerbation of symptoms, emotional distress, poor illness perception, 
educational and behavioural issues, and compromised employability and insurability.
149,150
 Psychological 
condition is correlated with depression, anxiety, and impaired QoL.
149,151
 Possible interventions at 
improving illness perceptions may enhance patients' QoL, by increasing patients' knowledge regarding 
their disease and informing patients about treatment options, psychosocial support, cognitive behavioural 
therapies, and palliative care.
149 
 
They need life-long comprehensive care to which nurses are an integral part of the health-care 
team.
152–154




Heart failure in adult patients with congenital heart disease overshadows more and more the outcome 
of this patient population. No large randomized clinical trials are available to write guidelines with a 
certain level of evidence. However, HF strategies, effective in ischaemic and congestive heart disease, are 
frequently applied to patients with congenital heart defects. This position paper intends to offer a platform 
to parallelize HF treatment in the congenital heart disease community abroad. However, it is clear that 
more research is needed to reach a certain level of evidence-based medicine. 
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